Start the conversation
Minerva Neurosciences Inc. (Nasdaq: NERV) is a clinical-stage biotech company that focuses on central nervous system diseases. Through its IPO, NERV is looking to raise $33 million by offering 5.5 million shares for $6 each. NERV is expected to have a valuation of approximately $187 million following the IPO. The company had initially planned to price shares between $10 and $12, but announced today (Monday) that it was reducing the size of its IPO by 45%. NERV will trade on the Nasdaq.